Cargando…

Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China

BACKGROUND: The zero-markup drug policy (also known as the universal zero-markup drug policy (UZMDP)) was implemented in stages beginning with primary healthcare facilities in 2009 and eventually encompassing city public hospitals in 2016. This policy has been a central pillar of Chinese health refo...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zixuan, Zhan, Chaohong, Ma, Xiaomeng, Yao, Honghui, Chen, Xu, Sha, Xinping, Coyte, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571884/
https://www.ncbi.nlm.nih.gov/pubmed/34742310
http://dx.doi.org/10.1186/s12913-021-07211-8
_version_ 1784595109909626880
author Peng, Zixuan
Zhan, Chaohong
Ma, Xiaomeng
Yao, Honghui
Chen, Xu
Sha, Xinping
Coyte, Peter C.
author_facet Peng, Zixuan
Zhan, Chaohong
Ma, Xiaomeng
Yao, Honghui
Chen, Xu
Sha, Xinping
Coyte, Peter C.
author_sort Peng, Zixuan
collection PubMed
description BACKGROUND: The zero-markup drug policy (also known as the universal zero-markup drug policy (UZMDP)) was implemented in stages beginning with primary healthcare facilities in 2009 and eventually encompassing city public hospitals in 2016. This policy has been a central pillar of Chinese health reforms. While the literature has examined the impacts of this policy on healthcare utilization and expenditures, a more comprehensive and detailed assessment is warranted. The purpose of this paper is to explore the impacts of the UZMDP on inpatient and outpatient visits as well as on both aggregate healthcare expenditures and its various components (including drug, diagnosis, laboratory, and medical consumables expenditures). METHODS: A pre-post design was applied to a dataset extracted from the Changde Municipal Human Resource and Social Security Bureau comprising discharge data on 27,246 inpatients and encounter data on 48,282 outpatients in Changde city, Hunan province, China. The pre-UZMDP period for the city public hospitals was defined as the period from October 2015 to September 2016, while the post-UZMDP period was defined as the period from October 2016 to September 2017. Difference-in-Difference negative binomial and Tobit regression models were employed to evaluate the impacts of the UZMDP on healthcare utilization and expenditures, respectively. RESULTS: Four key findings flow from our assessment of the impacts of the UZMDP: first, outpatient and inpatient visits increased by 8.89 % and 9.39 %, respectively; second, average annual inpatient and outpatient drug expenditures fell by 4,349.00 CNY and 1,262.00 CNY, respectively; third, average annual expenditures on other categories of healthcare expenditures increased by 2,500.83 CNY, 417.10 CNY, 122.98 CNY, and 143.50 CNY for aggregate inpatient, inpatient diagnosis, inpatient laboratory, and outpatient medical consumables expenditures, respectively; and fourth, men and older individuals tended to have more inpatient and outpatient visits than their counterparts. CONCLUSIONS: Although the UZMDP was effective in reducing both inpatient and outpatient drug expenditures, it led to a sharp rise in other expenditure categories. Policy decision makers are advised to undertake efforts to contain the growth in total healthcare expenditures, in general, as well as to evaluate the offsetting effects of the policy on non-drug components of care.
format Online
Article
Text
id pubmed-8571884
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85718842021-11-08 Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China Peng, Zixuan Zhan, Chaohong Ma, Xiaomeng Yao, Honghui Chen, Xu Sha, Xinping Coyte, Peter C. BMC Health Serv Res Research BACKGROUND: The zero-markup drug policy (also known as the universal zero-markup drug policy (UZMDP)) was implemented in stages beginning with primary healthcare facilities in 2009 and eventually encompassing city public hospitals in 2016. This policy has been a central pillar of Chinese health reforms. While the literature has examined the impacts of this policy on healthcare utilization and expenditures, a more comprehensive and detailed assessment is warranted. The purpose of this paper is to explore the impacts of the UZMDP on inpatient and outpatient visits as well as on both aggregate healthcare expenditures and its various components (including drug, diagnosis, laboratory, and medical consumables expenditures). METHODS: A pre-post design was applied to a dataset extracted from the Changde Municipal Human Resource and Social Security Bureau comprising discharge data on 27,246 inpatients and encounter data on 48,282 outpatients in Changde city, Hunan province, China. The pre-UZMDP period for the city public hospitals was defined as the period from October 2015 to September 2016, while the post-UZMDP period was defined as the period from October 2016 to September 2017. Difference-in-Difference negative binomial and Tobit regression models were employed to evaluate the impacts of the UZMDP on healthcare utilization and expenditures, respectively. RESULTS: Four key findings flow from our assessment of the impacts of the UZMDP: first, outpatient and inpatient visits increased by 8.89 % and 9.39 %, respectively; second, average annual inpatient and outpatient drug expenditures fell by 4,349.00 CNY and 1,262.00 CNY, respectively; third, average annual expenditures on other categories of healthcare expenditures increased by 2,500.83 CNY, 417.10 CNY, 122.98 CNY, and 143.50 CNY for aggregate inpatient, inpatient diagnosis, inpatient laboratory, and outpatient medical consumables expenditures, respectively; and fourth, men and older individuals tended to have more inpatient and outpatient visits than their counterparts. CONCLUSIONS: Although the UZMDP was effective in reducing both inpatient and outpatient drug expenditures, it led to a sharp rise in other expenditure categories. Policy decision makers are advised to undertake efforts to contain the growth in total healthcare expenditures, in general, as well as to evaluate the offsetting effects of the policy on non-drug components of care. BioMed Central 2021-11-06 /pmc/articles/PMC8571884/ /pubmed/34742310 http://dx.doi.org/10.1186/s12913-021-07211-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Peng, Zixuan
Zhan, Chaohong
Ma, Xiaomeng
Yao, Honghui
Chen, Xu
Sha, Xinping
Coyte, Peter C.
Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China
title Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China
title_full Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China
title_fullStr Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China
title_full_unstemmed Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China
title_short Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China
title_sort did the universal zero-markup drug policy lower healthcare expenditures? evidence from changde, china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571884/
https://www.ncbi.nlm.nih.gov/pubmed/34742310
http://dx.doi.org/10.1186/s12913-021-07211-8
work_keys_str_mv AT pengzixuan didtheuniversalzeromarkupdrugpolicylowerhealthcareexpendituresevidencefromchangdechina
AT zhanchaohong didtheuniversalzeromarkupdrugpolicylowerhealthcareexpendituresevidencefromchangdechina
AT maxiaomeng didtheuniversalzeromarkupdrugpolicylowerhealthcareexpendituresevidencefromchangdechina
AT yaohonghui didtheuniversalzeromarkupdrugpolicylowerhealthcareexpendituresevidencefromchangdechina
AT chenxu didtheuniversalzeromarkupdrugpolicylowerhealthcareexpendituresevidencefromchangdechina
AT shaxinping didtheuniversalzeromarkupdrugpolicylowerhealthcareexpendituresevidencefromchangdechina
AT coytepeterc didtheuniversalzeromarkupdrugpolicylowerhealthcareexpendituresevidencefromchangdechina